Drug-loaded PLGA nanoparticles for oral administration: Fundamental issues and challenges ahead

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 29, Issue 1, 2012, Pages 149-182

  Kumar, Gaurav ^a   Shafiq, Nusrat ^a   Malhotra, Samir ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Challenges and issues; Nanoparticle characterization; Nanotechnology; PLGA

Indexed keywords

AMIFOSTINE; ATORVASTATIN; CURCUMIN; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; ELLAGIC ACID; ESTRADIOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ETHIONAMIDE; HEPARIN; HUMAN GROWTH HORMONE; INSULIN; MIFEPRISTONE; NANOPARTICLE; OCTREOTIDE; PACLITAXEL; POLYCAPROLACTONE; POLYGLACTIN; ROLIPRAM; STREPTOMYCIN; SURODEX; TAMOXIFEN; TRIPTORELIN; UBIDECARENONE; UNCLASSIFIED DRUG; VORICONAZOLE; ALPHA TOCOPHEROL SUCCINATE; POLYMER; TUBERCULOSTATIC AGENT;

BIOCOMPATIBILITY; CELL CULTURE; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HYDROPHILICITY; IMMUNOTOXICITY; IN VITRO STUDY; INFLAMMATION; ISOTOPE LABELING; NANOENCAPSULATION; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; REVIEW; SCALE UP; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ACROMEGALY; BREAST CANCER; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; COLON CANCER; DIABETES MELLITUS; DRUG HALF LIFE; DRUG SAFETY; DRUG UPTAKE; DYSLIPIDEMIA; ENTERITIS; GRAFT REJECTION; GROWTH RETARDATION; HYPERLIPIDEMIA; HYPERTENSION; INSTRUMENT STERILIZATION; LUNG EMBOLISM; MYCOSIS; MYELOMA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; TUBERCULOSIS; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; LACTIC ACID; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; POLYGLYCOLIC ACID; TECHNOLOGY, PHARMACEUTICAL;

EID: 84860365715     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v29.i2.20     Document Type: Review

References (127)

1. Li M, Rouaud O, Poncelet D. Microencapsulation by solvent evaporation: state of the art for process engineering approaches. Int J Pharm. 2008; 363: 26-39.
2. Stevanovic M, Maksin T, Petkovic J, Filipic M, Uskokovic D. An innovative, quick and convenient labeling method for the investigation of pharmacological behavior and the metabolism of poly (DL-lactide-co-glycolide) nanospheres. Nanotechnol. 2009; 20: 1-12.
3. Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R, Kumar MNVR. Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotech. 2005; 1: 235-58.
4. Florence AT. The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997;14: 259-66.
5. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990; 42: 821-6.
6. Sahana DK, Mittal G, Bhardwaj V, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticles formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci. 2007; 9999:1-13.
7. Pandey R, Khuller GK. Polymer-based drug delivery systems for mycobacterial infections. Curr Drug Deliv. 2004; 1: 195-201.
8. Huh KM, Cho YW, Park K. PLGA-PEG block copolymers for drug formulations. Drug Deliv Technol. 2003; 3: 42-9.
9. Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J Control Release. 2010; 141: 300-2.
10. Vines T, Faunce T. Assessing the safety and cost-effectiveness of early nanodrugs. J Law Med 2009;16: 822-45.
11. R. Duncan. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003; 2: 347-60.
12. www.USFDA.gov/assessed on: 15/03/2011.
13. Dhawan A, Sharma V, Parmar D. Nanomaterials: a challenge for toxicologists. Nanotoxicol 2009; 3: 1-9.
14. Hirsjarvi S, Peltonen L, Kainu L, Hirvonen J. Freeze-drying of low molecular weight poly (L-lactic acid) nanoparticles: effect of cryo-and lyoprotectants. J Nanosci Nanotechnol. 2006; 6: 3110-7.
15. Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur J Pharm Biopharm. 2006; 63: 87-94.
16. Abdelwashed W, Degobert G, Stainmesse S, Fessi H. Freeze drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006; 58: 1688-713.
17. Sameti M, Bohr G, Ravi Kumar MNV, Kneuer C, Bakowsky U, Nacken M, Schmidt H, Lehr CM. Stabilization by freeze-drying of cationically modified silica nanoparticles for gene delivery. Int J Pharm. 2003; 266: 51-60.
18. Lee MK, Kim MY, Kim S, Lee J. Cryoprotectants for freeze drying of drug nano-suspensions: effect of freezing rate. J Pharm Sci. 2009; 98: 4808-17.
19. Lee J, Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release. 2006; 111: 185-92.
20. Saez A, Guzmán M, Molpeceres J, Aberturas MR. Freeze-drying of polycaprolactone and poly (D, L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm. 2000; 50:379-87.
21. Jain S, Mittal A, Jain AK, Mahajan RR, Singh D. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in vitro characterization and stability studies. Curr Nanosci. 2010; 6: 422-31.
22. Warheit DB. How meaningful are the results of nanotoxicity studies in the absence of adequate material charecterization. Toxicol Sci. 2008; 101: 183-5.
23. Dhawan A, Sharma V. Toxicity assessment of nanomaterials: methods and challenges. Anal Bioanal Chem. 2010; 398: 589-605.
24. Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, Swai HS. In vivo evaluation of the biodistribution and safety of PLGA nanopaticles as drug delivery systems. Nanomed: Nanotechnol Biol Med. 2010; 6: 662-71.
25. Powers KW, Palazuelos M, Moudgil BM, Roberts SM. Characterization of the size, shape, and state of dispersion of nanoparticles for toxicological studies. Nanotoxicol. 2007; 1: 42-51.
26. Murdock RC, Braydich-Stolle L, Schrand A M, Schlager JJ, Hussain SM. Characterization of nanomaterial dispersion in solution prior to in vitro exposure using dynamic light scattering technique. Toxicol Sci. 2008; 101: 239-53.
27. Davada J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002; 233: 51-9.
28. Weissenbock A, Wirth M, Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J Control Release. 2004; 99: 383-92.
29. Ahlin P, Kristl J, Kristl A, Vrecer F. Investigation of polymeric nanoparticles as carrier of enalaprilat for oral administration. Int J Pharm. 2002; 239: 113-20.
30. Gaumet M, Gurny R, Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur J Pharm Sci. 2009; 36: 465-73.
31. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008; 69:1-9.
32. Hall JB, Dobrovolskaia MA, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine. 2007; 2: 789-803.
33. Furumoto K, Ogawara K, Nagayama S, Takakura Y, Hashida M, Higaki K, Kimura T. Important role of serum proteins associated on the surface of particles in their hepatic disposition. J Control Release. 2002; 83: 89-96.
34. Borkovec M. Measuring particle size by light scattering. In: Holmberg K, editor. Handbook of applied surface and colloid chemistry. New Jersey: John Wiley; 2002. p. 357-70.
35. Montes-burgos I, Walcyk D, Hole P, Smith J, lynch I, Dawson KA. Characterisation of nanoparticle size and state prior to nanotoxicoogical studies. J Nanopart Res. 2010;12: 47-53.
36. Jones C, Grainger DW. In vitro assessment of nanomaterial toxicity. Adv Drug Deliv Reviews. 2009; 61: 438-56.
37. Duclairoir C, Nakache E. Polymer nanoparticle characterization in aqueous suspensions. Int J Polym Anal Charact. 2002; 7: 284-313.
38. Scalf J, West P. Part I: Introduction to nanoparticles characterization with AFM. Pacific Nanotechnology Inc, Santa Clara; 2006 (cited 2011, Jan 21). Available from: www.nanoparticles.org/pdf/Scalf-West.pdf/assessed.
39. Berg JM, Romoser A, Banerjee N, Zebda R, Sayes CM. The relationship between pH and zeta potential of ~ 30 nm metal oxide nanoparticle suspensions relevant to in vitro toxicological evaluations. Nanotoxicol. 2009; 3: 276-83.
40. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, Sioutas C, Yeh JI, Wiesner MR, Nel AE. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 2006; 6: 1794-807.
41. Lundqvist M, Stigler J, Giuliano E, Lynch I, Cedervall T, Dawson K. Nanoparticle size and surface properties determine the protein corona with possibles implications for biological impacts. PNAS. 2009; 105: 14265-70.
42. Nan A, Bai X, Son SJ, Lee SB, Ghandehari H. Celluar uptake and cytotoxicity of silica nanotubes. Nano Lett. 2008; 8: 2150-4.
43. Beak DG, Basta NT, Scheckel KG, Traina SJ. Bioaccessibility of arsenic (V) bound to ferrihydrate using a simulated gastrointestinal system. Environ Sci Technol. 2006; 40: 1364-70.
44. Rodriguez R, Basta N, Casteel S, Pace LW. An in vitro gatrointestinal method to estimate bioavailable arsenic in contaminated soils and solid media. Environ Sci Technol. 1999; 33: 642-9.
45. Furumoto K, Nagayama S, Ogawara K, Takakura Y, Hashida M, Higaki K, Kimura T. Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J Control Release. 2004; 97: 133-41.
46. Cael V, Van der Heyden A, Champmartin D, Barzyk W, Rubini P, Rogalska E. Interfacial approach to aluminium toxicity: interactions of Al(III) and Pr (III) with model phospholipid bilayer and monolayer membranes. Langmuir. 2003; 19: 8697-708.
47. Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro-and nanoscale drug delivery carriers. J Control Release. 2007; 121: 3-9.
48. Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA. 2008; 105: 11613-8.
49. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects, Curr Pharm Design. 2010; 16: 2298-307.
50. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Materials. 2009; 8: 15-23.
51. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res. 2009; 26: 244-249.
52. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA. 2006; 103: 4930-4.
53. Florence AT. Pharmaceutical nanotechnology: more than size ten topics for research. Int J Pharm. 2007; 339: 1-2.
54. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: does geometry really matter? Pharm Res. 2009; 26: 235-43.
55. Yoo JW, Doshi N, Mitragotri S. Endocytosis and intracellular distribution of PLGA particles in endothelial cells: effect of particles geometry. Macromol Rapid Commun. 2009;31: 142-8.
56. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998; 24: 1113-28.
57. Matsumoto A, Kitazawa T, Murata J, Horikiri Y, Yamahara H. A novel preparation method for PLGA microspheres using non-halogenated solvents. Pharm Res. 1996; 13: 360-7.
58. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide). Nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002; 82: 105-14.
59. Feng SS, Huang GF. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release. 2001; 71: 53-69.
60. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J Control Release. 2002; 80: 129-44.
61. Snodin DJ. An EU perspectives on the use of an in vitro methods in regulatory pharmaceutical toxicology. Toxicol Lett 2002; 127: 161-8.
62. Kroll A, Pillukat MH, Hahn D, Schnekenburger J. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur J Pharm Biopharm. 2009;72: 370-7.
63. Fernandez-Caballed A, Pastoriza P, Barcia E, Montejo C, Negro S. PLGA/PEG-derivative polymeric matrix for drug delivery system applications: characterisation and cell viability studies. Int J Pharm. 2008; 352: 50-7.
64. Marquis BJ, Love SA, Braun KL, Haynes CL. Analytical methods to assess nanoparticle toxicity. Analyst. 2009; 134: 425-39.
65. Prior S, Gander B, Blarer N, Merkle HP, Subira ML, Irache JM, Gamazo C. In vitro phagocytosis and monocyte-macrophage activation with poly (lactide) and poly (lactide-co-glycolide) microspheres. Eur J Pharm Sci. 2002; 15: 197-207.
66. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005; 26: 2713-22.
67. Delie F, Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst. 1997; 14: 221-86.
68. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990; 42: 821-6.
69. Jepson MA, Simmons NL, O'Hagan DT., Hirst BH. Comparison of poly (d, l-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target. 1993; 1: 245-9.
70. Belyanskaya L, Manser P, Spohn P, Bruinink A, Wick P. The reliability and limits of the MTT reduction assay for carbon nanotubes-cell interaction. Carbon. 2007; 45: 2643-8.
71. Nachalas MM, Margulies SI, Goldberg JD, Seligman AM. The determination of lactic dehydrogenase with a tetrazolium salt. Anal Biochem. 1960; 1: 317.
72. Casey A, Herzog E, Davoren M, Lyng FM, Byrne HJ, Chambers G. Spectroscopic analysis confirms the interactions between single walled carbon nanotubes and various dyes commonly used to assess cytotoxicity. Carbon. 2007;45: 1425-32.
73. Shukla S, Priscilla A, Banerjee M, Bhonde RR, Ghatak J, Satyam PV, Sastry M. Porous gold nanospheres by controlled transmetalation reaction: a novel material for application in cell imaging. Chem Mater. 2005; 17: 5000-5.
74. Shang L, Zoua X, Jianga X, Yanga G, Dong S. Investigations on the adsorption behavior of neutral red on mercaptoethane sulfonate protected gold nanoparticles. J Photochem Photobiol. A: Chem. 2006; 187: 152-9.
75. 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000; 65: 133-48.
76. Stone V, Donaldson K. Nanotoxicology: signs of stress. Nat Nanotechnol. 2006; 1: 23-4.
77. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolite of oxygen and nitrogen: in vitro and in vivo consideration. Am J Physiol Regul Integr Comp Physiol. 2004; 286: R431-R444.
78. Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, Leppens H, Ponti J, Stritzinger R, Puntes V, Boraschi D, Duschl A, Oostingh GJ. The suitability of different cellular in vitro immunotoxicty and genotoxicty method for the analysis of nanoparticles-induced events. Nanotoxicol. 2010; 4: 52-72.
79. Monteiro-Riviere NA, Inman AO. Challenges for assessing carbon nanomaterial toxicity to the skin. Carbon. 2006; 44: 1070-8.
80. Vernath JM, Kaser EG, Vernath MM, Koch M, Yost GS. Cytokine responses of human lung cells (BEAS-2B) treated with micron-sized and nanoparticles of metal oxides compared to soil dusts. Part Fibre Toxicol. 2007; 4: 2.
81. Guo L, Von Dem Bussche A, Buechner M, Yan A, Kane AB, Hurt RH. Adsorption of essential micronutrients by carbon nanotubes and the implication of nanotoxicty testing. Small. 2008; 4: 721-7.
82. Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Reviews. 2009; 61: 1220-31.
83. Durrer C, Irache J, Duchene D, Ponchel G. Study of the interactions between nanoparticles and intestinal mucosa. Prog Colloid Polym Sci. 1994; 97: 275-80.
84. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990; 42: 821-6.
85. Sonaje K, Italia JL, Sharma G, Bhardwaj V, Tikoo K, Ravi Kumar MNV. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antoioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm Res. 2007; 24: 899-908.
86. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MNV. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res. 2006; 23: 184-95.
87. Shakweh M, Besnard M, Nicolas V, Fattal E. Poly (lactide-co-glycolide) particles of different physiochemical properties and their uptake by peyer's patches in mice. Eur J pharm Biopharm. 2005; 61: 1-13.
88. Yang YY, Wang Y, Powell R, Chan P. Polymeric core-shell nanoparticles for therapeutics. Clin Exp Pharmacol Physiol. 2006; 33: 557-62.
89. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J Pharm Sci. 2000; 87: 1229-34.
90. Delie F, Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst. 1997; 14: 221-86.
91. Gaumet M, Gurny R, Delie F. Interaction of biodegradable nanoparticles with intestinal cells: The effect of surface hydrophilicity. Int J Pharm. 2010; 390: 45-52.
92. Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, Cheng J-X, Kohane DS, Yeo Y. Intracellular drug delivery by poly (lactic-co-glycolic) acid nanoparticles, revisited. Mol Pharm. 2009; 6: 190-201.
93. DLlactide-co-glyolide) nanoparticles after intravenous and oral administration to mice. Int J Pharm. 1994; 106: 201-11.
94. Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicines Nat Nanotechnol. 2008; 3: 242-44.
95. Nigavekar SS, Sung LY, Llanes M, El-Jawaahri A, Lawrence TS, Becker CW, Balogh L, Khan MK. 3H dendrimer nanoparticles organ/tumor distribution. Pharm Res. 2004; 21: 476-83.
96. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010; 145: 182-95.
97. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly (D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003; 20: 212-20.
98. Qaddoumi MG, Ueda H, Yang J, Davada J, Labhasetwar V, Lee VH. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004; 21: 641-8.
99. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm. 2009; 382: 198-204.
100. Mo Y, Lim LY. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. J Pharm Sci. 2004; 93: 20-8.
101. Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? In: Ivanov AI, Walker JM, editors. Methods in molecular biology. USA: Humanna Press; 2008. p. 15-33.
102. Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat Cell Biol. 2006; 8: 46-54.
103. Damm E-M, Pelkmans L, Kartenbeck J, Mezzacasa A, Kurzchalia T, Helenius A. clathrin-and caveolin-1-independent endocytosis: entry of smian virus 40 into cells devoid of caveolae. J Cell Biol. 2005; 168: 477-88.
104. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell permeable inhibitor of dynamin. Dev Cell. 2006; 10: 839-50.
105. Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm. 1998; 24: 703-27.
106. Bala I, Hariharan S, Ravi Kumar MNV. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004; 21: 387-422.
107. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009; 26: 492-501.
108. Pandey R, Sharma S, Khuller GK. Oral poly (lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: Toxicological and chemotherapeutic implications. Ind J Exp Biol. 2006; 44: 459-67.
109. Kumar G, Sharma S, Shafiq N, Pandhi P, Khuller GK, Malhotra S. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Drug Deliv. 2011; 18: 65-73.
110. Carino GP, Jacob JS, Mathiowitz E. Nanosphere-based oral insulin delivery. J Control Rel. 2000; 65: 261-9.
111. Cui F, Tao A, Cun D, Zhang L, Shi K. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci. 2007; 96: 421-7.
112. Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr C-M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2001; 299: 775-81.
113. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, Maincent P. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation. 2002; 105: 230-5.
114. Jaiswal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. J Control Release. 2004; 96: 169-78.
115. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to sand immune Neoral. J Control Release. 2007; 119: 197-206.
116. Pamujula S, Graves RA, Freeman T, Srinivasan V, Bostanian LA, Kishore V, Mandal TK. Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharm Pharmacol. 2004; 56: 1119-25.
117. Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MN. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J Drug Target. 2006; 14: 27-34.
118. Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the brain in experimental model. J Antimicrob Chemother. 2006; 57: 1146-52.
119. Ankola D, Viswanad B, Bhardwaj V, Ramarao P, Ravi Kumar MNV. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional suppliments be used as first line therapeutic agents for prophylaxsis/therapy? Eur J Pharm Biopharm. 2007; 67: 361-9.
120. He W, Horn SW, Hussain MD. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm. 2007; 334: 173-8.
121. Pandey R, Khuller GK. Nanoparticles-based oral drug delivery system for an injectable antibiotic-streptomycin. Evaluation in a murine tuberculosis model. Chemother. 2007; 53: 437-41.
122. Peng HS, Liu XJ, Lv GX, Sun B, Kong QF, Zhai DX, Wang Q, Zhao W, Wang GY, Wang DD, Li HL, Jin LH, Kostulas N. Voriconazole into PLGA nanoparticles: improving agglomeration and antifungal efficacy. Int J Pharm. 2008; 352: 29-35.
123. Meena AK, Venkat Ratnam D, Chandraiah G, Ankola DD, Rama Rao P, Ravi Kumar MNV. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to lipicure in treating hyperlipidemia. Lipids. 2008; 43: 231-41.
124. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr C-M, Ravi Kumar MNV. PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res. 2009; 26: 2495-503.
125. Mittal G, Chandraiah G, Ramarao P, Ravi Kumar MN. Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model. Pharm Res. 2009; 26: 218-23.
126. Jain AK, Swarnakar NK, Godugu C, Singh RP, Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 2011; 32: 503-15.
127. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, Wang H, Zhou Q, Yu S. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem. 2011; 59: 9280-9. t